Close
    Share
    Facebook Facebook icon Twitter Twitter icon LinkedIn LinkedIn icon Email

    Tech for Good

    PlayPlay Video

    Bioversys: ‘Impact investors should focus more on equitable health’

    August 22, 2023 • by Jim Pulcrano in Tech for Good

    With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of...

    With investors increasingly focusing on ESG topics, you might think that being a Tech for Good company would help attract funding. This is not always the case, says Marc Gitzinger, CEO of Bioversys, which is developing new medicines for severe life-threatening bacterial infections that are resistant to antibiotics. 

    In episode five, Gitzinger says the biotech industry still focuses mainly on financial returns and calls on impact investors to pay more attention to the topic of equitable health to ensure access and proper control of good quality drugs throughout the world. 

    Gitzinger discusses how he defines success, including the importance of generating financial returns for the investors who have believed in the technology and backed the business. 

    Expert

    Marc Gitzinger is Chief Executive Officer and co-founder of BioVersys with over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset clinical stage company.

    Marc Gitzinger

    CEO and co-founder of BioVersys

    Marc is Chief Executive Officer and co-founder of BioVersys with over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset clinical stage company. 

    Authors

    Jim Pulcrano

    Adjunct Professor of Entrepreneurship and Management

    Jim Pulcrano is an IMD Adjunct Professor of Entrepreneurship and Management. His current projects include teaching in Lausanne, London and Silicon Valley, research on disruption, and various strategy, networking, customer-centricity, and innovation mandates with multinationals in Europe, Asia, and the US. At IMD, He is Director of the Venture Capital Asset Management (VCAM) program and teaches on the Executive MBA (EMBA), Orchestrating Winning Performance (OWP), and full-time MBA programs.

    More to explore

    Wistia:
    X

    Log in or register to enjoy the full experience

    Explore first person business intelligence from top minds curated for a global executive audience

    Register NowSign in